
FIH Partners advised the Danish biotech company Glycom in investing more than 500 million DKK in the acquisition and adaptation of the Vitalys’ manufacturing facility in Esbjerg, Denmark, to secure production capacity for significant international growth.
Glycom focuses on the development, synthesis and commercialization of human milk oligosaccharides (HMOs) with the ambition to improve human health by making HMOs and their benefits broadly available. The investment has been funded by major Danish financial institutions and the existing shareholders.
FIH Partners acted as exclusive financial advisor to Glycom